bluebird bio, Inc. (BLUE)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 11:41AM EDT. Market open.
| Previous close | 0.9530 |
| Open | 0.9500 |
| Bid | 0.9793 x 1800 |
| Ask | 0.9944 x 700 |
| Day's range | 0.9400 - 0.9946 |
| 52-week range | 0.8800 - 5.5300 |
| Volume | |
| Avg. volume | 8,598,432 |
| Market cap | 190.371M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript
bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript March 26, 2024 bluebird bio, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to bluebird bio Fourth Quarter and 2023 Annual Results Conference Call. At this […]
- Simply Wall St.
bluebird bio, Inc.'s (NASDAQ:BLUE) top owners are retail investors with 51% stake, while 49% is held by institutions
Key Insights Significant control over bluebird bio by retail investors implies that the general public has more power...
- Motley Fool
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.
© 2024 Yahoo. All rights reserved.